Ficha de colecciones : Museo Anatómico Pedro Ara

El Museo Anatómico Pedro Ara, dependiente de la Facultad de Ciencias Médicas de la Universidad Nacional de Córdoba tiene su cimiento en el año 1878 con la finalidad de enseñar la materia de Anatomía; en ese momento contaba con un esqueleto prestado por el Colegio Nacional de Monserrat , nueve preparados, algunos huesos realizados en la Cátedra, otros obtenidos en Cementerio San Jerónimo, un atlas anatómico y nueve láminas.Eje: PostersRed de Museos de la Universidad Nacional de La Plat

Ficha de colecciones : Museo Anatómico Pedro Ara

El Museo Anatómico Pedro Ara, dependiente de la Facultad de Ciencias Médicas de la Universidad Nacional de Córdoba tiene su cimiento en el año 1878 con la finalidad de enseñar la materia de Anatomía; en ese momento contaba con un esqueleto prestado por el Colegio Nacional de Monserrat , nueve preparados, algunos huesos realizados en la Cátedra, otros obtenidos en Cementerio San Jerónimo, un atlas anatómico y nueve láminas.Eje: PostersRed de Museos de la Universidad Nacional de La Plat

Ficha de colecciones : Museo Anatómico Pedro Ara

El Museo Anatómico Pedro Ara, dependiente de la Facultad de Ciencias Médicas de la Universidad Nacional de Córdoba tiene su cimiento en el año 1878 con la finalidad de enseñar la materia de Anatomía; en ese momento contaba con un esqueleto prestado por el Colegio Nacional de Monserrat , nueve preparados, algunos huesos realizados en la Cátedra, otros obtenidos en Cementerio San Jerónimo, un atlas anatómico y nueve láminas.Eje: PostersRed de Museos de la Universidad Nacional de La Plat

Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study

Anaplastic large-cell lymphoma; Progression-free survivalLinfoma anaplásico de células grandes; Supervivencia libre de progresiónLimfoma anaplàsic de cèl·lules grans; Supervivència lliure de progressióWe investigated the clinicopathological features and prognostic factors of patients with peripheral T-cell lymphoma (PTCL) in 13 sites across Spain. Relevant clinical antecedents, CD30 expression and staining pattern, prognostic indices using the International Prognostic Index and the Intergruppo Italiano Linfomi system, treatments, and clinical outcomes were examined. A sizeable proportion of 175 patients had a history of immune-related disorders (autoimmune 16%, viral infections 17%, chemo/radiotherapy-treated carcinomas 19%). The median progression-free survival (PFS) and overall survival (OS) were 7·9 and 15·8 months, respectively. Prognostic indices influenced PFS and OS, with a higher number of adverse factors resulting in shorter survival (P 15% of cells were positive in anaplastic lymphoma kinase-positive and -negative anaplastic large-cell lymphoma and extranodal natural killer PTCL groups. We observed PTCL distribution across subtypes based on haematopathological re-evaluation. Poor prognosis, effect of specific prognostic indices, relevance of histopathological sub-classification, and response level to first-line treatment on outcomes were confirmed. Immune disorders amongst patients require further examination involving genetic studies and identification of associated immunosuppressive factors.This study was sponsored by Takeda

Ritmo, danza y música como estrategia de mejoramiento de la movilidad de las personas con enfermedad de Parkinson

El Taller de Parkinson (TdP) es una metodología no-farmacológica complementaria al tratamiento medicamentoso que se desarrolla con el objetivo de mejorar la calidad de vida de las personas con EP mediante la estimulación de la movilidad y expresión corporal (cfr. Dillon et al, 2010). El marco teórico subyacente es el de la kinesia paradojal (cfr. Souqués, 1921 y Asmus et al, 2008), sabiendo que las personas con EP son capaces de moverse como si no tuvieran la enfermedad dado cierto entorno estimulador y ciertas disposiciones emocionales, cognitivas y motrices de los pacientes con Parkinson. De esta forma, en el TdP se desarrollan entornos que puedan contener las condiciones para que las personas con Parkinson puedan desplegar su movilidad, siendo uno de ellos el espacio de danza, a cargo del Prof. Carlos Sánchez.Facultad de Ciencias Médica

Ritmo, danza y música como estrategia de mejoramiento de la movilidad de las personas con enfermedad de Parkinson

El Taller de Parkinson (TdP) es una metodología no-farmacológica complementaria al tratamiento medicamentoso que se desarrolla con el objetivo de mejorar la calidad de vida de las personas con EP mediante la estimulación de la movilidad y expresión corporal (cfr. Dillon et al, 2010). El marco teórico subyacente es el de la kinesia paradojal (cfr. Souqués, 1921 y Asmus et al, 2008), sabiendo que las personas con EP son capaces de moverse como si no tuvieran la enfermedad dado cierto entorno estimulador y ciertas disposiciones emocionales, cognitivas y motrices de los pacientes con Parkinson. De esta forma, en el TdP se desarrollan entornos que puedan contener las condiciones para que las personas con Parkinson puedan desplegar su movilidad, siendo uno de ellos el espacio de danza, a cargo del Prof. Carlos Sánchez.Facultad de Ciencias Médica

LEARNING STYLES IN HYBRID EDUCATION PROCESSES

A documentary review was carried out on the production and publication of research papers related to the study of the variables Learning Styles and Hybrid Education. The purpose of the bibliometric analysis proposed in this paper was to know the main characteristics of the volume of publications registered in the Scopus database during the period 2016-2021, achieving the identification of 92 publications. The information provided by the said platform was organized through tables and figures, categorizing the information by Year of Publication, Country of Origin, Area of Knowledge and Type of Publication. Once these characteristics were described, the position of different authors regarding the proposed topic was referenced by applying qualitative analysis. Among the main findings of this research, it is found that the United States, with 26 publications, was the country with the highest scientific production registered in the name of authors affiliated with institutions of that country. The Knowledge Area that made the greatest contribution to the construction of bibliographic material referring to the study of the different learning styles in hybrid education processes was Computer Science with 49 published documents, and the type of publication that was most used during the above-mentioned period was the conference article, which represents 53% of the total scientific production

Management of Pediatric Mild Traumatic Brain Injury Patients: S100b, Glial Fibrillary Acidic Protein, and Heart Fatty-Acid-Binding Protein Promising Biomarkers.

Children are highly vulnerable to mild traumatic brain injury (mTBI). Blood biomarkers can help in their management. This study evaluated the performances of biomarkers, in discriminating between children with mTBI who had intracranial injuries (ICIs) on computed tomography (CT+) and (1) patients without ICI (CT-) or (2) both CT- and in-hospital-observation without CT patients. The aim was to rule out the need of unnecessary CT scans and decrease the length of stay in observation in the emergency department (ED). Newborns to teenagers (≤16 years old) with mTBI (Glasgow Coma Scale > 13) were included. S100b, glial fibrillary acidic protein (GFAP), and heart fatty-acid-binding protein (HFABP) performances to identify patients without ICI were evaluated through receiver operating characteristic curves, where sensitivity was set at 100%. A total of 222 mTBI children sampled within 6 h since their trauma were reported. Nineteen percent (n = 43/222) underwent CT scan examination, whereas the others (n = 179/222) were kept in observation at the ED. Sixteen percent (n = 7/43) of the children who underwent a CT scan had ICI, corresponding to 3% of all mTBI-included patients. When sensibility (SE) was set at 100% to exclude all patients with ICI, GFAP yielded 39% specificity (SP), HFABP 37%, and S100b 34% to rule out the need of CT scans. These biomarkers were even more performant: 52% SP for GFAP, 41% for HFABP, and 39% for S100b, when discriminating CT+ versus both in-hospital-observation and CT- patients. These markers can significantly help in the management of patients in the ED, avoiding unnecessary CT scans, and reducing length of stay for children and their families

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel or tisa-cel were retrospectively collected from 12 Spanish centers. A total of 307 patients underwent apheresis for axi-cel (n=152) and tisa-cel (n=155) from November 2018 to August 2021, of which 261 (85%) received a CAR T infusion (88% and 82%, respectively). Median time from apheresis to infusion was 41 days for axi-cel and 52 days for tisa-cel (P=0.006). None of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs. 73%, P=0.003, and 42% vs. 16%, P= 2 and progressive disease before lympho-depletion. Safety and efficacy results in our real-world experience were comparable with those reported in the pivotal trials. Patients treated with axi-cel experienced more toxicity but similar non-relapse mortality compared with those re-ceiving tisa-cel. Efficacy was not significantly different between both products

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel or tisa-cel were retrospectively collected from 12 Spanish centers. A total of 307 patients underwent apheresis for axi-cel (n=152) and tisa-cel (n=155) from November 2018 to August 2021, of which 261 (85%) received a CAR T infusion (88% and 82%, respectively). Median time from apheresis to infusion was 41 days for axi-cel and 52 days for tisa-cel (P =0.006). None of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs. 73%, P =0.003, and 42% vs. 16%, P <0.001, respectively). Infections in the first 6 months post-infusion were also more common in patients treated with axi-cel (38% vs. 25%, P =0.033). Non-relapse mortality was not significantly different between the axi-cel and tisa-cel groups (7% and 4%, respectively, P =0.298). With a median follow-up of 9.2 months, median PFS and OS were 5.9 and 3 months, and 13.9 and 11.2 months for axi-cel and tisa-cel, respectively. The 12-month PFS and OS for axi-cel and tisa-cel were 41% and 33% (P =0.195), 51% and 47% (P =0.191), respectively. Factors associated with lower OS in the multivariate analysis were increased lactate dehydrogenase, ECOG ≥2 and progressive disease before lympho-depletion. Safety and efficacy results in our real-world experience were comparable with those reported in the pivotal trials. Patients treated with axi-cel experienced more toxicity but similar non-relapse mortality compared with those receiving tisa-cel. Efficacy was not significantly different between both products